Pell Bio-Med Technology , Ltd. EBIT

The latest EBIT for 6949.TW is $-510M as of June 2026. That compares with $-360M in the prior-year period — down 39.7% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Pell Bio-Med Technology , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 6949.TW's EBIT moved from $-360M to $-510M — a 39.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pell Bio-Med Technology , Ltd.'s operating scale or balance-sheet position.

Against Healthcare companies, 6949.TW currently prints $-510M for EBIT, while the sector average sits near $110B. That is roughly 100.5% below the sector mean. Large gaps often invite a closer look at Pell Bio-Med Technology , Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $-510M for 6949.TW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting 6949.TW's EBIT ($-510M), review year-over-year change from $-360M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.